[1] VENERITO M, LINK A, ROKKAS T, et al. Gastric cancer-clinical and epidemiological aspects[J]. Helicobacter, 2016, Suppl 1: 39-44. [2] 陈万青,张思维,曾红梅,等.中国2010年恶性肿瘤发病与死亡[J].中国肿瘤,2014,23(1):1-10. [3] LORDICK F, ALLUM W, CARNEIRO F, et al.Unmet needs and challenges in gastric cancer: the way forward[J]. Cancer Treat Rev, 2014, 40(6): 692-700. [4] 王芳,柳江,罗健,等.晚期胃癌化疗及分子靶向治疗研究进展[J].中国医师杂志,2016,18(1):18-21. [5] LI J, QIN S, XU J, et al.Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial[J]. J Clin Oncol, 2013, 31(26): 3219-3225. [6] KOZLOFF M, YOOD M U, BERLIN J, et al.Clinical outcomes associated with bevacizumab containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study[J]. Oncologist, 2009, 14(9): 862-870. [7] 汤兴华,刘雄,章宜兰,等.腹腔镜辅助下远端胃癌D2根治术治疗进展期胃癌的疗效及安全性[J].中国肿瘤临床与康复,2015,22(6):656-658. [8] 巴一,周礼鲲.晚期胃癌的化疗选择[J].中国肿瘤临床,2016,43(1):21-26. [9] LIGNET F, BENZEKRY S,WILSON S, et al.Theoretical investigation of the efficacy of antiangiogenic drugs combined to chemotherapy in xenografted mice[J]. J Theor Biol, 2013, 320: 86-99. [10] 王博,宋丽杰,牛鹏云,等.阿帕替尼治疗晚期胃癌的临床疗效及预后[J].世界华人消化杂志,2016,24(5):759-764. [11] LI J, QIN S, XU J, et al.Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase Ⅱ trial[J]. J Clin Oncol, 2013, 31(26): 3219-3225. [12] 周阳阳,秦叔逵,汪蕊,等.阿帕替尼治疗晚期胃癌伴顽固性癌性腹水4例[J].临床肿瘤学杂志,2016,21(5):476-478. [13] 高金平,韩涛,朴瑛,等.阿帕替尼联合替吉奥治疗老年或瘦弱患者晚期胃癌临床研究[J].临床军医杂志,2017,45(1):9-12. |